Neoadjuvant (induction) erlotinib response in stage IIIA non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 26, Issue 25, 2008, Pages 4205-4207

  Kappers, Ingrid ^a   Klomp, Houke M ^a   Burgers, Jacobus A ^a   Van Zandwijk, Nico ^a   Haas, Rick L M ^a   Van Pel, Renée ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUORODEOXYGLUCOSE F 18;

ADJUVANT THERAPY; AGED; ARTICLE; ASPIRATION BIOPSY; CANCER RADIOTHERAPY; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; EXON; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SKIN TOXICITY; THORACOTOMY;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; NEOADJUVANT THERAPY; POSITRON-EMISSION TOMOGRAPHY; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; REMISSION INDUCTION; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 51649114273     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.16.3709     Document Type: Article

References (1)

1. van Zandwijk N, Mathy A, Boerrigter L, et al: EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: Retro- and prospective observations in non-small-cell lung cancer. Ann Oncol 18:99-103, 2007